Literature DB >> 25349809

Effects of medication methods after simple and effective probing of lacrimal passage.

Bin Lu1, Hua-Ying Xie1, Cai-Ping Shi1, Chun-Si Xu1, Mei-Hong Gu1.   

Abstract

AIM: To evaluate the effect of reducing the use of antibiotics in the treatment of infant bacterial dacryocystitis after probing of the lacrimal duct.
METHODS: A total of 542 cases of children under one year old and accepting nasolacrimal duct probing treatment were divided into two groups, which were treated with topical and oral antibiotics, respectively. Conjunctival sac secretions were used as a control index of bacterial infection, whereas the disappearance of epiphora symptoms and lacrimal passage patency were used as cure indexes. The χ (2) test was used to compare enumeration and measurement data, and a statistical significance was set at P<0.05. The therapeutic effect on the two groups of postoperative patients was investigated.
RESULTS: In the two study groups, no significant differences in gender, age and postoperative control of lacrimal sac infection were observed. The cure rates after three probing operations also showed no significant difference.
CONCLUSION: After probing of the lacrimal passage, results of this study confirmed that postoperative medication without oral antibiotics but an ophthalmic dosage of antibiotics was a simple and effective treatment method.

Entities:  

Keywords:  dacryocystitis; infant; lacrimal passage obstruction; lavage

Year:  2014        PMID: 25349809      PMCID: PMC4206897          DOI: 10.3980/j.issn.2222-3959.2014.05.24

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  20 in total

1.  [Bacteriology of occluded nasolacrimal ducts in infants].

Authors:  V Prokosch; J-E Prokosch; J Promesberger; S Thanos; T Stupp
Journal:  Klin Monbl Augenheilkd       Date:  2010-07-19       Impact factor: 0.700

2.  A national survey of the management of congenital nasolacrimal duct obstruction in the United kingdom.

Authors:  Narman Puvanachandra; Sameer Trikha; Caroline J MacEwen; Robert J Morris; Peter R Hodgkins
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2010-03-22       Impact factor: 1.402

3.  Intraoperative prognostic factors for probing outcome in children with congenital nasolacrimal duct obstruction.

Authors:  Dima Andalib; Reza Nabei
Journal:  Eur J Ophthalmol       Date:  2012-11-19       Impact factor: 2.597

4.  Evaluation of treatment modalities and prognostic factors in children with congenital nasolacrimal duct obstruction.

Authors:  Yasser H Al-Faky; Nora Al-Sobaie; Ahmad Mousa; Hessa Al-Odan; Reem Al-Huthail; Essam Osman; Abdul Rahman Al-Mosallam
Journal:  J AAPOS       Date:  2012-02       Impact factor: 1.220

5.  Success rates of endoscopic-assisted probing for congenital nasolacrimal duct obstruction in children.

Authors:  S Theodoropoulou; M S M Sutherland; K Haddow; A Blaikie
Journal:  J Laryngol Otol       Date:  2013-06-27       Impact factor: 1.469

6.  Presentation and management of congenital dacryocystocele.

Authors:  Rupa Krishnamurthy Wong; Deborah K VanderVeen
Journal:  Pediatrics       Date:  2008-10-27       Impact factor: 7.124

7.  The microbiologic spectrum of dacryocystitis: a national study of acute versus chronic infection.

Authors:  David M Mills; Marc G Bodman; Dale R Meyer; Asa D Morton
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2007 Jul-Aug       Impact factor: 1.746

8.  Probing without irrigation in children with congenital nasolacrimal duct obstruction.

Authors:  Gloria Isaza; Sourabh Arora
Journal:  Clin Invest Med       Date:  2013-06-01       Impact factor: 0.825

9.  Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases.

Authors:  Matthew S Benz; Ingrid U Scott; Harry W Flynn; Nichard Unonius; Darlene Miller
Journal:  Am J Ophthalmol       Date:  2004-01       Impact factor: 5.258

Review 10.  Management of congenital nasolacrimal duct obstruction.

Authors:  Yasuhiro Takahashi; Hirohiko Kakizaki; Weng O Chan; Dinesh Selva
Journal:  Acta Ophthalmol       Date:  2009-07-21       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.